Loading
A phase 1/2 trial of HLA-G-CAR.BiTE allogeneic γδ T cells in advanced solid tumours, run by Ever Supreme Bio Technology Co., Ltd., now recruiting.
A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT06150885 by Ever Supreme Bio Technology Co., Ltd., with 60 participants planned, started 2024-09-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: HLA-G-CAR.BiTE allogeneic γδ T cells.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/